14 Drugs Approved for Primary Care in 2020
Get a quick look at 14 of the many FDA-approved drugs in 2020 for conditions commonly seen in primary care.
The year 2020 has been one-of-a-kind as the novel coronavirus disease 2019 (COVID-19) began to spread globally just after the new year and "social distancing" has become everyday language.
Just like this unique year, there were a number of drugs approved by the US Food and Drug Administration (FDA) that were first-in-class or novel in another way in all 4 quarters of 2020. For example, the first and only FDA-approved COVID-19 treatment; the first adjuvanted, cell-based flu vaccine for use in persons aged ≥6 months; and a first-in-class adenosine triphosphate-citrate lyase inhibitor to treat heterozygous familial hypercholesterolemia. In the slides below, we recap these drugs and 11 more to prepare primary care clinicians for 2021.
FDA Accepts Protocol for Annovis Bio’s Buntanetap Phase 3 Alzheimer Disease Trial
January 9th 2025Buntanetap is an oral molecule designed to inhibit the production of multiple neurotoxic proteins and is under investigation for treatment of Alzheimer Disease, Parkinson’s Disease, and other neurodegenerative diseases.
